Recent additions
Reviewed 28 September 20262026Network meta-analysis
Long-acting growth hormones in East Asia: comparative efficacy and safety
Liu Q, Wu C, Peng D, et al. · Endocrine Practice. 32(8):1303–1310. · Online 1 April; issue August 2026.
This five-study network analysis included Pegpesen, Jintrolong, and somapacitan. For height velocity, the Pegpesen estimate versus daily GH was −0.10 cm/year (95% CI −0.53 to 0.32). The authors reported more favorable growth estimates for Jintrolong. Differences in adverse-event and serious-adverse-event rates were not statistically significant.
Interpretation: comparisons between long-acting products are indirect. Wide safety intervals and a small evidence network limit certainty; these findings do not establish a direct head-to-head advantage. Summary based on the published abstract.
2026Conference abstract
Pegpesen in non-GHD short stature: a Phase II basket trial
Liang Y and colleagues · ENDO 2026, oral abstract ORF47-04. · 15 June 2026.
The randomized, open-label, 52-week study enrolled 78 children with idiopathic short stature (ISS), small for gestational age (SGA), or Turner syndrome (TS). The abstract reports dose-response modeling and growth findings for weekly Pegpesen versus daily rhGH, with similar reported safety profiles between groups.
Preliminary conference evidence, not a full journal paper. These populations and investigational regimens should not be treated as additional approved indications or dosing recommendations.
2026Population PK/PD
Optimizing Pegpesen dosing through population PK/PD modeling
Zhao Y, Zou F, Gu J, He R, Yin Y. · Journal of Endocrinological Investigation. 49:599–607. · Online 5 November 2025; issue March 2026.
Data from the Phase I–III program informed simulations in 292 children with GHD. The model explored quarterly dose escalation and weight-banded dosing; modeled growth responses converged by month 24.
This is a modeling study. Its simulated titration and weight bands are research proposals, not replacements for approved dosing instructions.
The core clinical program
Product-specific studies2025Randomized Phase III
Weekly Y-shaped PEGylated rhGH in children with GHD
Liang Y, Wei H, Yang F, et al. · The Journal of Clinical Endocrinology & Metabolism. 110:e2605–e2613. · Online 28 November 2024; 2025 issue.
The pivotal, active-controlled trial randomized 391 treatment-naïve children with GHD to weekly Pegpesen or daily somatropin. The 52-week analysis met the prespecified growth-velocity non-inferiority criterion.
Read efficacy together with adverse events, immunogenicity, the study population, and the duration of follow-up.
2022Randomized Phase II
Dose-ranging, PK/PD, and short-term growth outcomes
Liang Y, Zhang C, Wei H, et al. · Frontiers in Endocrinology. 13:922304. · 11 August 2022.
A multicenter study in 43 children evaluated three once-weekly PEGylated rhGH doses against daily rhGH over 12 weeks, characterizing exposure, IGF-1 response, and short-term growth.
The short treatment period and small groups limit conclusions about long-term outcomes.
Wider GH context
Background reading · not Pegpesen-specific evidence2025Consensus
Long-acting GH therapy in pediatric GHD: international consensus
The Journal of Clinical Endocrinology & Metabolism · PMID 39672599.
Field-level guidance addressing long-acting GH treatment, monitoring, adherence, and remaining evidence gaps.
Class-level guidance should not be used to assume that different GH products have interchangeable doses or identical evidence.
Search scope: Pegpesen, inpegsomatropin, and Y-shaped PEGylated recombinant human growth hormone. Sources reviewed include PubMed, journal publishers, and the Endocrine Society’s ENDO 2026 program. Online-publication and journal-issue dates are shown separately where relevant. This is a curated reference list, not a systematic review. Local PDFs retained from the existing library.
